<DOC>
	<DOCNO>NCT01636882</DOCNO>
	<brief_summary>This extend use study patient receive 10 dos CAVATAKâ„¢ VLA 007 trial . There may patient benefit study drug might benefit treatment . In order accommodate patient treatment complete 48 week CVA21 intratumoral injection make available .</brief_summary>
	<brief_title>Efficacy Safety Intratumoral CAVATAK Patients With Stage IIIc IV Malignant Melanoma Extend Dosing 48 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Patients must reach Week 24 core protocol immunerelated complete response ( irCR ) , immunerelated partial response ( irPR ) , immunerelated stable disease ( irSD ) , immunerelated progressive disease ( irPD ) ( unconfirmed ) evidence tumor inflammatory reaction . 2 . If patient irPD ( unconfirmed ) status , must decrease Karnofsky Performances Scale ( KPS ) score &gt; 10 point judge `` rapid clinical deterioration '' investigator since subject 's last tumor measurement lead irPD assessment . 3 . Patients must start treatment extension protocol within 8 week last injection administer core protocol . 4 . Patient able willing provide write informed consent participate study . 5 . Fertile male female must agree use adequate form contraception , e.g. , condom male . 1 . Tumors inject lie mucosal region close airway , major blood vessel spinal cord , opinion Investigators , could cause occlusion compression case tumor swell erosion major vessel case necrosis . 2 . If lesion small visualize palpable accurate injection . 3 . Currently status irPD ( confirm ) irPD ( unconfirmed ) without evidence tumor inflammatory response , rapid clinical deterioration , decrease 10 point KPS score since last assessment irPD ( unconfirmed ) assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>CALM</keyword>
</DOC>